

Supplementary Online Content


Bauer DC, Schwartz A, Palermo L, et al. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. *JAMA Intern Med*. Published online May 5, 2014. doi:10.1001/jamainternmed.2014.1232

eFigure 1. Change in Hip BMD Among Women Discontinuing Alendronate (FLEX Placebo Group)

eFigure 2. Change in Bone Turnover Markers Among Women Discontinuing Alendronate (FLEX Placebo Group)

This supplementary material has been provided by the authors to give readers additional information about their work.


eFigure 1. Change in Hip BMD Among Women Discontinuing Alendronate (FLEX Placebo Group)




PBO indicates placebo group.

eFigure 2. Change in Bone Turnover Markers Among Women Discontinuing Alendronate (FLEX Placebo Group)

a. Bone Specific Alkaline Phosphatase (BSAP)



b. Urinary NTX: Creatinine Ratio



PBO indicates placebo group.